



# CERTIFICATE OF ANALYSIS




## Product Details

Product name:	Anti-IL-17 & IL-17F & Serum Albumin Reference Antibody (Sonelokimab)	Lot.No.:	P247905
Target:	IL-17 / IL-17A / CTLA-8, IL-17F, Serum Albumin / SA / HSA	Catalog:	CHBA006
Target Accession:	Q16552 & Q96PD4 & P02768	Concentration :	1 mg/mL
Clonality:	Bispecific	Isotype:	VHH-VHH-VHH
Reactivity:	Human	Molecular Weight (kDa) :	40.93 kDa
Application:	Kinetics (SPR), ELISA, Bioactivity: FACS, Functional assay, Research in vivo	Endotoxin:	<1 EU/mg
Formulation:	Liquid: 100mM Pro-Ac, 20mM Arg pH 5.0   Lyophilization: 25mM histidine, 8% sucrose, 0.01% Tween80 pH6.2	Conjugation:	Unconjugated
Reconstitution:	For Powder, reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.	Expression System:	CHO
Storage:	Upon receipt, store immediately at -20°C or lower for 24 months. Store aliquots at -80°C for up to 3 months. Avoid repeated freeze-thaw cycles.	Purification:	Protein A


# Data

## MASS




The detected molecular weight of Anti-IL-17 & IL-17F & Serum Albumin Reference Antibody (Sonelokimab) is 40.93 kDa.

## Purity: SDS-PAGE




Anti-IL-17 & IL-17F & Serum Albumin Reference Antibody (Sonelokimab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

## Purity: SEC-HPLC



The purity of Anti-IL-17 & IL-17F & Serum Albumin Reference Antibody (Sonelokimab) is 98.70%, determined by SEC-HPLC.


## ELISA



Sonelokimab bound to IL-17F protein, and then rebounded to secondary antibodies (Anti-human-IgG-His-HRP), and read OD450. As shown in fig, Sonelokimab bound in hu-IL-17F-Fc, and the EC50 was 0.009 nM.


The products are for research use only. Not for use in diagnostic procedures.

## ELISA



Sonelokimab bound to HSA protein, and then rebounded to secondary antibodies (Anti-human-IgG-His-HRP), and read OD450. As shown in fig, Sonelokimab bound in hu-HSA-Fc, and the EC<sub>50</sub> was 0.022nM.

## Functional assay



Co-incubation of NHDF cells with TNF- $\alpha$  and IL-17A protein, then with the addition of Sonelokimab and incubated for 24 hours. IL-6 was measured by ELISA. As shown in fig 3, Sonelokimab can neutralize IL17-A-induced IL-6 factor secretion, and the IC<sub>50</sub> was 2.877 nM.

The products are for research use only. Not for use in diagnostic procedures.